Business Wire
26 Jun 2026, 10:49 UTC · 12w ago
Verdict
Headline leans bullish. We score ACAD +0.90 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
The EMA's CHMP has issued a positive opinion recommending marketing authorization for DAYBU (trofinetide) for Rett syndrome in adults and children aged five and older.
More positive than 98% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 95% of ticker scores this week
The EMA's CHMP issued a positive opinion recommending marketing authorization for its drug DAYBU for Rett syndrome.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
2d ago
+15.1%
Price agrees with the score
$27.29 vs $23.72 close before publication (Jun 25) · not market-adjusted
ACAD chart →
